Loading stock data…
Atrium Therapeutics (RNA)
$11.35-2.84 (-20.01%)
Market ClosedLast close Sep 8
Atrium Therapeutics, Inc., a biopharmaceutical company, focuses on delivering ribonucleic acid (RNA) therapeutics to the heart to transform the care for people living with cardiomyopathies.
Historical Price
Price (Candle)
Synthesizing Whystock Narrative...
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $19.64M↑ | $859,000↓ | $12.47M↑ | $3.85M↑ | $1.57M |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$17.28M↑ | -$48.03M↑ | -$188.81M↓ | -$171.14M↓ | -$7.45M |
| Net Income | -$16.63M↑ | -$48.07M↑ | -$174.44M↓ | -$157.31M↓ | -$7.45M |
Peer Comparison
JNJUNHPFE
Fundamentals
Atrium Therapeutics, Inc., a biopharmaceutical company, focuses on delivering ribonucleic acid (RNA) therapeutics to the heart to transform the care for people living with cardiomyopathies. The company's development stage product candidates include A...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$213.74M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-169.35%
Volume
Today's trading volume
1.71M
Recent News
Wall Street Money Is Leaving Just As Atrium’s (RNA) Pipeline Turns Real
On August 13, Atrium Therapeutics (NASDAQ:RNA) reported second-quarter 2026 results that mixed real clinical progress with a familiar biotech question: how long the cash lasts. The company disclosed FDA clearance of its IND application for ATR 1072 and the launch of Corventis, its first Phase 1/2 trial and the first study anywhere testing a disease-modifying […]
Can Atrium Therapeutics (RNA)’s $15 Million Milestone From Bristol-Myers Squibb (BMY) Validate its RNA Platform?
On August 13, two pharmaceutical companies tied to the same cardiovascular research deal delivered major updates. Atrium Therapeutics, Inc. (NASDAQ:RNA) earned a $15 million milestone payment from Bristol-Myers Squibb Company (NYSE:BMY) after delivering a lead RNA compound targeting an undisclosed cardiology indication. The payment stems from a global collaboration eligible to yield Atrium up to […]
Zillow downgraded, Global Payments upgraded: Wall Street's top analyst calls
Zillow downgraded, Global Payments upgraded: Wall Street's top analyst calls
Here's Why We're Not Too Worried About Atrium Therapeutics' (NASDAQ:RNA) Cash Burn Situation
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Novartis Uses US Bond Issue To Expand RNA And Peptide Pipeline
Novartis (SWX:NOVN) issues US$11b in US dollar bonds to fund its planned US$12b acquisition of Avidity Biosciences. The bond financing highlights the company’s focus on expanding its medicines portfolio through large-scale M&A. Separately, Novartis signs a licensing agreement with Unnatural Products for macrocyclic peptide therapeutics targeting cardiovascular disease. Both moves add new platforms and modalities to the Novartis pipeline beyond recent product approvals and corporate...